245 related articles for article (PubMed ID: 21840762)
1. Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study.
Infanti L; Stebler C; Job S; Ruesch M; Gratwohl A; Irsch J; Lin L; Buser A
Transfus Apher Sci; 2011 Oct; 45(2):175-81. PubMed ID: 21840762
[TBL] [Abstract][Full Text] [Related]
2. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment.
Osselaer JC; Messe N; Hervig T; Bueno J; Castro E; Espinosa A; Accorsi P; Junge K; Jacquet M; Flament J; Corash L
Transfusion; 2008 Jun; 48(6):1061-71. PubMed ID: 18346019
[TBL] [Abstract][Full Text] [Related]
3. Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients.
Schlenke P; Hagenah W; Irsch J; Sundin D; Corash L; Lin L; Kirchner H; Wagner T
Ann Hematol; 2011 Dec; 90(12):1457-65. PubMed ID: 21503644
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
Janetzko K; Cazenave JP; Klüter H; Kientz D; Michel M; Beris P; Lioure B; Hastka J; Marblie S; Mayaudon V; Lin L; Lin JS; Conlan MG; Flament J
Transfusion; 2005 Sep; 45(9):1443-52. PubMed ID: 16131376
[TBL] [Abstract][Full Text] [Related]
5. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.
Snyder E; McCullough J; Slichter SJ; Strauss RG; Lopez-Plaza I; Lin JS; Corash L; Conlan MG;
Transfusion; 2005 Dec; 45(12):1864-75. PubMed ID: 16371039
[TBL] [Abstract][Full Text] [Related]
6. Patient and product factors affecting platelet transfusion results.
Heim D; Passweg J; Gregor M; Buser A; Theocharides A; Arber C; Meyer-Monard S; Halter J; Tichelli A; Gratwohl A
Transfusion; 2008 Apr; 48(4):681-7. PubMed ID: 18208413
[TBL] [Abstract][Full Text] [Related]
7. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
[TBL] [Abstract][Full Text] [Related]
8. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
Sigle JP; Infanti L; Studt JD; Martinez M; Stern M; Gratwohl A; Passweg J; Tichelli A; Buser AS
Transfusion; 2013 Aug; 53(8):1788-97. PubMed ID: 23176347
[TBL] [Abstract][Full Text] [Related]
9. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.
Murphy S; Snyder E; Cable R; Slichter SJ; Strauss RG; McCullough J; Lin JS; Corash L; Conlan MG;
Transfusion; 2006 Jan; 46(1):24-33. PubMed ID: 16398727
[TBL] [Abstract][Full Text] [Related]
10. Prospective observational study of low thresholds for platelet transfusion in adult dengue patients.
Thomas L; Kaidomar S; Kerob-Bauchet B; Moravie V; Brouste Y; King JP; Schmitt S; Besnier F; Abel S; Mehdaoui H; Plumelle Y; Najioullah F; Fonteau C; Richard P; Césaire R; Cabié A
Transfusion; 2009 Jul; 49(7):1400-11. PubMed ID: 19320862
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
[TBL] [Abstract][Full Text] [Related]
12. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
Osselaer JC; Doyen C; Defoin L; Debry C; Goffaux M; Messe N; Van Hooydonk M; Bosly A; Lin JS; Lin L; Corash L
Transfusion; 2009 Jul; 49(7):1412-22. PubMed ID: 19389022
[TBL] [Abstract][Full Text] [Related]
13. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
Wiita AP; Nambiar A
Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
[TBL] [Abstract][Full Text] [Related]
15. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment.
Osselaer JC; Cazenave JP; Lambermont M; Garraud O; Hidajat M; Barbolla L; Tardivel R; Defoin L; Waller C; Mendel I; Raidot JP; Kandel G; De Meuter R; Fabrigli P; Dehenau D; Arroyo JL; Padrón F; Gouezec H; Corral M; Jacquet M; Sundin D; Lin L; Corash L
Vox Sang; 2008 May; 94(4):315-23. PubMed ID: 18248574
[TBL] [Abstract][Full Text] [Related]
16. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
[TBL] [Abstract][Full Text] [Related]
17. Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses.
Arnold DM; Crowther MA; Cook RJ; Sigouin C; Heddle NM; Molnar L; Cook DJ
Transfusion; 2006 Aug; 46(8):1286-91. PubMed ID: 16934061
[TBL] [Abstract][Full Text] [Related]
18. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study.
Simonsen AC; Johansson PI; Conlan MG; Jacquet M; Lin JS; Junge K; Lin L; Sørensen H; Borregaard N; Flament J
Transfusion; 2006 Mar; 46(3):424-33. PubMed ID: 16533286
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.
Mirasol Clinical Evaluation Study Group
Transfusion; 2010 Nov; 50(11):2362-75. PubMed ID: 20492615
[TBL] [Abstract][Full Text] [Related]
20. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.
Pineda A; McCullough J; Benjamin RJ; Cable R; Strauss RG; Burgstaler E; Porter S; Lin L; Metzel P; Conlan MG;
Transfusion; 2006 Apr; 46(4):562-71. PubMed ID: 16584432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
